Oklahoma City residents concerned about diabetes or obesity have an opportunity to evaluate their health and wellness at no cost. EmVenio Research, a clinical research organization, is offering free health screenings at its mobile community research site, located at 1301 N. Portland Ave., outside Portland Avenue Baptist Church. The screenings will test patients for Type 2 diabetes, obesity and other weight-related conditions.
“In Oklahoma City, more than 1 in 3 residents are classified as obese and 13% have Type 2 diabetes,” said Niambi Blodgett, EmVenio’s director of global patient engagement. “By offering this free service, we can open the gateway for residents to rediscover their health and begin a new path to wellness.”
Niambi Blodgett; Director, Global Patient Engagement
EmVenio’s screening at its Oklahoma City site offers A1C blood sampling, calculations for body mass index, measurements for basic vital signs, and vision and memory exams. EmVenio will provide the results to the patient and refer them to local physicians, including those who serve uninsured and underinsured patients.
“Access to affordable health care is the first step in one’s path to wellness,” Blodgett said. “Populations without health insurance or access to care face a higher risk of chronic health conditions. We want residents to feel empowered by options and the opportunity to take control of their health and well-being.”
Niambi Blodgett; Director, Global Patient Engagement
Individuals interested in a free health screening can sign up at exerciseyouroptions.com.
About EmVenio Research
EmVenio Research provides rapid and scalable mobile community research site solutions to better reach and recruit diverse, underserved, high-risk communities. EmVenio Research’s global network of skilled clinicians, principal investigators and state-of-the-art mobile community research sites enable us to provide robust clinical research services via home visits, on-site support at medical facilities, virtual visits and mobile sites. Visit emvenio.com to learn more.